Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,
Disease:Carcinoma
Product details:
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ICOSLG, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ICOS Ligand also known as ICOSL B7-H2 and HK53 is a critical component in immune system function. This protein with a molecular mass of approximately 65 kDa is expressed on professional antigen-presenting cells such as dendritic cells macrophages and B cells. It plays a significant mechanical role in the immune response by engaging with its counter receptor the ICOS protein present on the surface of activated T cells. This interaction supports the regulation of T cell activity influencing proliferation and cytokine production.
Biological function summary
ICOSL contributes to the modulation of immune responses. By forming a complex with the active ICOS protein ICOSL is involved in the co-stimulation of T cells. This process is important for the development of T-cell-dependent immune responses and helps in promoting the survival and differentiation of T cells. Together the ICOS ligand and ICOS protein create a dynamic interaction that balances immune activation and tolerance which is essential for maintaining immune homeostasis.
Pathways
The ICOS-ICOSL interaction plays an important role in the T-cell receptor (TCR) signaling pathway. This pathway is fundamental for the activation of T cells and subsequent immune response. ICOSL also connects to the PI3K/Akt pathway where it impacts cell survival and proliferation. ICOS and the PI3K/Akt pathway work together to influence various aspects of immune regulation and adaptive immunity.
ICOSL has a notable impact on autoimmune diseases and cancer. Its function in immune modulation when dysregulated can contribute to autoimmune conditions such as systemic lupus erythematosus. In this context the abnormal activation of the ICOS protein may exaggerate immune responses leading to pathology. In cancer high expression of ICOSL can support tumor progression by affecting the immune surveillance capability. These associations reveal ICOSL’s role in balancing immune activation and inhibition which is important in the context of disease.
